Funding for this research was provided by:
Received: 23 December 2019
Accepted: 25 May 2020
First Online: 10 June 2020
Ethics approval and consent to participate
: Written informed consent was obtained from all participants before screening. This study received Institutional Review Board approval, was conducted in accordance with the Declaration of Helsinki, and was registered as EudraCT 2016-000104-29.
: Not applicable.
: MW has received compensation for consulting and lecture activities from Mylan Inc, Allergopharma, and ALK-Abelló. DTN is an employee of Meda Pharma GmbH & Co KG. AM has received speaker fees from Aimmune Therapeutics, DVB Technologies, Mylan Inc, ALK-Abelló, and Nestlé Purina. GDT has received honoraria from Mylan Inc. RR, TL, HL, and KB are employees of and may own stock in Mylan Inc. M Wickman has no competing interests.